MedElevator
Войти в исследования European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery · 2025
Rivaroxaban Does Not Alter Carotid Plaque Echolucency, Volume, or Neovascularisation.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jessen Majken L, Yeung Karin, Collet-Billon Antoine, Eiberg Jonas, Sillesen Henrik, Eldrup Nikolaj
Аннотация
OBJECTIVE: This study investigated the effects of rivaroxaban on echolucency, volume, and neovascularisation in atherosclerotic carotid plaques compared with placebo in a randomised controlled study design.
METHODS: A double blind, randomised, placebo controlled, single centre clinical trial was conducted. Results were reported according to the CONSORT guidelines. Patients with non-critical peripheral arterial disease were screened for asymptomatic carotid disease and included if a plaque in the carotid artery thicker than 2.5 mm was present. Patients were randomised to either rivaroxaban 2.5 mg twice daily or placebo in addition to aspirin and statins. Patients were followed for 12 months with evaluation visits at three, six, and 12 months, which included ultrasound (US) imaging, testing blood samples, and safety assessment. The primary outcome was change in US plaque echolucency as measured in grayscale median (GSM) over time. Secondary outcomes included changes in plaque volume and intraplaque neovascularisation (IPN). Safety and cardiovascular events were assessed at all visits. Plaque echolucency, volume, and neovascularisation were assessed with three dimensional US and two dimensional contrast enhanced US imaging. The most echolucent plaque by GSM in each patient identified at baseline was monitored prospectively (Clinical Trials Information System trial no. 2024-518539-13-00).
RESULTS: Initially, 62 patients were included, 31 received rivaroxaban and 31 placebo. Final analyses included 28 patients in the rivaroxaban group and 29 patients in the placebo group. There were no differences between the groups in plaque GSM value, and GSM was unchanged over time in both groups. No difference was found in the change in plaque volume or IPN score over time.
CONCLUSION: In patients with peripheral arterial disease and echolucent carotid plaques, treatment with rivaroxaban did not alter carotid plaque echolucency, volume, or IPN.
METHODS: A double blind, randomised, placebo controlled, single centre clinical trial was conducted. Results were reported according to the CONSORT guidelines. Patients with non-critical peripheral arterial disease were screened for asymptomatic carotid disease and included if a plaque in the carotid artery thicker than 2.5 mm was present. Patients were randomised to either rivaroxaban 2.5 mg twice daily or placebo in addition to aspirin and statins. Patients were followed for 12 months with evaluation visits at three, six, and 12 months, which included ultrasound (US) imaging, testing blood samples, and safety assessment. The primary outcome was change in US plaque echolucency as measured in grayscale median (GSM) over time. Secondary outcomes included changes in plaque volume and intraplaque neovascularisation (IPN). Safety and cardiovascular events were assessed at all visits. Plaque echolucency, volume, and neovascularisation were assessed with three dimensional US and two dimensional contrast enhanced US imaging. The most echolucent plaque by GSM in each patient identified at baseline was monitored prospectively (Clinical Trials Information System trial no. 2024-518539-13-00).
RESULTS: Initially, 62 patients were included, 31 received rivaroxaban and 31 placebo. Final analyses included 28 patients in the rivaroxaban group and 29 patients in the placebo group. There were no differences between the groups in plaque GSM value, and GSM was unchanged over time in both groups. No difference was found in the change in plaque volume or IPN score over time.
CONCLUSION: In patients with peripheral arterial disease and echolucent carotid plaques, treatment with rivaroxaban did not alter carotid plaque echolucency, volume, or IPN.